Platelet [3H]paroxetine binding to 5-HT uptake sites in Alzheimer's disease.
Platelet serotonin (5-hydroxytryptamine, 5-HT) uptake sites were studied in a control group (n = 30) and an Alzheimer group (n = 40) using [3H]paroxetine as radioligand. The maximum number of binding sites (Bmax) for control (1250 +/- 60 fmol/mg protein) was not different from the Alzheimer group (1280 +/- 40 fmol/mg protein). There were no differences in apparent binding affinity (Kd): 0.046 (0.024-0.062) nM for control and 0.040 (0.027-0.061) nM for Alzheimer. Thus even though several previous studies have demonstrated marked atrophy of 5-HT containing neurites and 5-HT uptake sites in Alzheimer's disease, these findings are not found in the periphery on platelets. The platelet 5-HT uptake site cannot be used as a peripheral marker of Alzheimer's disease.
Andersson
A
A
Department of Geriatric Medicine, University of Umeå, Sweden.
Adolfsson
R
R
Eriksson
K
K
Marcusson
J
J
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood*; D001792:Blood Platelets / Q000378:metabolism*; D005260:Female; D006801:Humans; D007099:Imipramine / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D017374:Paroxetine; D010880:Piperidines / Q000378:metabolism* / Q000493:pharmacokinetics; D011869:Radioligand Assay; D011985:Receptors, Serotonin / Q000378:metabolism*; D012727:Sex Characteristics
D010880:Piperidines; D011985:Receptors, Serotonin; D017374:Paroxetine; D007099:Imipramine